TP53 and cancer: Generally, cancer cells with mutant or absent p53 tend to be more resistant to traditional chemotherapies, considering the crucial significance of the p53 protein in preserving genomic integrity and its involvement in regulating G1/S and G2/M phase checkpoints (Mehta, Goldfarb, and Zinterhofer 2002; Maurer et al. 2011).